Head-to-Head Comparison
OpenEvidence vs Doximity: Which Is Better for Physicians?
OpenEvidence: AI Research Assistant for Evidence-Based Clinical Decisions Doximity: The Professional Medical Network with AI-Powered Tools
Updated
Direct Answer
Source: Clinical AI Report, 2026
Key takeaways
- OpenEvidence draws on content partnerships with NEJM, JAMA, NCCN, ACC, AAFP and ACEP, plus 300+ journals and FDA and CDC sources, for cited answers.
- Doximity Ask, formerly DoxGPT, adds 3,200+ drug monographs from the August 2025 Pathway Medical acquisition; that drug content is recent and still maturing.
- OpenEvidence has no drug dosing tools or differential diagnosis generator, and its EHR integration is early-stage, with a Sutter Health and Epic integration announced in February 2026.
- Doximity bundles Doximity Scribe, secure messaging, telehealth, a dialer and digital fax into one app, though its networking-heavy interface can distract from clinical lookups.
Feature Comparison
| Feature | OpenEvidence | Doximity |
|---|---|---|
| Rating | OpenEvidence: Good | Doximity: Good |
| Category | OpenEvidence: AI Medical Research Assistant | Doximity: Medical Professional Network & AI Tools |
| Pricing | OpenEvidence: Free (Ad-Supported) | Doximity: Free (Ad-Supported) |
| Founded | OpenEvidence: 2022 | Doximity: 2010 |
| Headquarters | OpenEvidence: Miami, FL | Doximity: San Francisco, CA |
| Evidence Citations | OpenEvidence: Yes | Doximity: Yes |
| AI Differential Diagnosis | OpenEvidence: No | Doximity: Yes |
| Drug Database | OpenEvidence: No | Doximity: Yes |
| Drug Interaction Checker | OpenEvidence: No | Doximity: No |
| Medical Calculators | OpenEvidence: Yes | Doximity: No |
| Natural Language Search | OpenEvidence: Yes | Doximity: Yes |
| Document & Image Upload | OpenEvidence: No | Doximity: Yes |
| EHR Integration | OpenEvidence: Yes | Doximity: No |
| Mobile App | OpenEvidence: Yes | Doximity: Yes |
| Built-in Dialer | OpenEvidence: Yes | Doximity: Yes |
| AI Clinical Scribe | OpenEvidence: No | Doximity: Yes |
| CME Credits | OpenEvidence: No | Doximity: Yes |
| Multi-Language | OpenEvidence: Yes | Doximity: No |
Strengths & Limitations
OpenEvidence
Strengths
- +Useful for generalist clinical questions — fast, cited answers for everyday practice
- +Widely adopted clinical AI in the US (757K+ physicians)
- +Free for all verified physicians
- +Broadest content partnership network: NEJM, JAMA (all 11 specialty journals), NCCN, ACC, AAFP, ACEP, ADA, AAOS, 300+ journals
- +Native iOS and Android apps with Home Screen widgets
- +Quick Consult and Deep Consult modes for different clinical needs
- +Built-in dialer for calling patients, pharmacies, and colleagues
- +Well-funded with strong investor backing ($12B valuation, $100M annual revenue)
Limitations
- –No differential diagnosis generation or drug dosing tools
- –Ad-supported revenue model (pharmaceutical/healthcare advertising)
- –EHR integration is early-stage (Sutter Health/Epic announced February 2026)
- –Preprint by Jagarapu et al. (2025) reported 41% accuracy on complex subspecialty scenarios
- –Clinical depth narrower than platforms with drug databases and medical calculators
Doximity
Strengths
- +Largest physician network in the US (3M+ members, ~85% of US physicians)
- +Ask is advertised as free for U.S. healthcare professionals; confirm account eligibility
- +Pathway Medical acquisition adds 3,200+ peer-reviewed drug monographs
- +PeerCheck physician review program (10,000+ medical experts, co-chaired by Eric Topol)
- +Evidence-based clinical answers grounded in structured medical literature
- +300,000+ clinicians actively using AI tools (Q3 FY2026)
- +AI Scribe for ambient clinical documentation
- +Secure HIPAA-compliant messaging and integrated telehealth
- +100+ health system enterprise deployments
Limitations
- –AI revenue not yet commercialized — long-term AI business model unproven
- –Networking-heavy interface can be distracting for clinical use
- –Pathway integration is recent (late 2025) — clinical depth still maturing
- –Company-published preference study lacks independent peer review
- –Revenue model relies on pharmaceutical and health system advertising
- –Check current Ask availability and workflow fit for your device and institution
Key Statistics
OpenEvidence
Doximity
Citable Summaries
OpenEvidence
OpenEvidence has an editorial score of 73/100 (3.7/5), calculated from Clinical AI Report's published criteria weights. It ranks #2 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Doximity
Doximity has an editorial score of 70/100 (3.5/5), calculated from Clinical AI Report's published criteria weights. It ranks #4 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Our Assessment
In our 2026 evaluation, OpenEvidence (ranked #2, 3.7 stars) outperforms Doximity (ranked #4, 3.5 stars) in overall physician satisfaction and editorial scoring. OpenEvidence is best suited for a useful tool for physicians who need fast, cited answers to clinical questions grounded in peer-reviewed literature. Relevant for primary care, internal medicine, and emergency medicine. Free and backed by a broad content partnership network (NEJM, JAMA, NCCN, ACC, AAFP, ACEP). Meanwhile, Doximity is a stronger choice for physicians already embedded in the Doximity ecosystem who want AI-powered clinical answers, drug reference, and documentation without switching platforms. Especially relevant for practices with enterprise Doximity contracts. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.